ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BCTX / insiders
BYSI (37) ABVC (32) CPHI (35) CELU (26) ⌘ Pro Terminal →

BriaCell Therapeutics Corp. (BCTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.09 +1.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.09

BriaCell Therapeutics Corp. (BCTX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $26.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BCTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BriaCell Therapeutics Corp. (NASDAQ: BCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.09 (+1.65% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, BCTX ranks #468 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BCTX compare to BYSI and ABVC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCTX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BCTX leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BCTX?
▼

Per BCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0001610820), BriaCell Therapeutics Corp. generated $76.2M in revenue (-18.4% YoY), -$26.3M in net income, and -$28.2M in free cash flow against $33.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.09 (+0.11%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (10)Whales (3)SEC (10)Macro (10)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$14 Bull$3 Base$2 Bear
📬 FREE BCTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY BCTX SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$3.71-6.7% Next Q
Q2 (-2Q)
45
Grade D$3.46+2.9% Next Q
Q3 (-1Q)
43
Grade D$3.56-13.2% Next Q
Current
40
Grade D-$3.09-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BCTX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.74) and Max Pain ($3.24) forces dealer call-delta covering toward $13.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BCTX Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

BCTX Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BCTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BCTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCTX)

  • ✓Walkthrough of BCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.45%🛡️ HOLDING TREND SUPPORT
2026-11-03O $3.31H $3.31L $3.04C $3.09VOL 130.9K
RES: $4.66SUP: $2.94SMA50: $3.74SMA200: $3.80
$7.73$6.34$4.95$3.56$2.17RES $4.66SUP $2.94$3.092026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCTX Butterfly Map → + Track BCTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -18.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCTX)

Health Care Rank #468 of 1015 ⚔️ BYSI vs BCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCTX vs. BYSI, ABVC, CPHI, CELU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BriaCell Therapeutics Corp. (BCTX) ranks #468 by composite RQD confidence (40/100, grade D-) and #810 by equity capitalization ($26.5M). Within this direct 5-issuer industry benchmark cohort, BCTX leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BCTX ACTIVE
BriaCell Therapeutics Corp.
D- 40/100 — — — +1.65% $26.5M Benchmark Subject
BYSI
BeyondSpring Inc.
D- 37/100 — — -35.0% +25.18% $26.5M /bysi-vs-bctx →
ABVC
ABVC BioPharma Inc.
E 32/100 — — -35.0% -1.99% $26.7M /abvc-vs-bctx →
CPHI
China Pharma Holdings Inc.
D- 35/100 — -3.2% -11.4% -2.98% $26.9M /cphi-vs-bctx →
CELU
Celularity Inc. (Class A)
E 26/100 — 24.4% -35.0% +0.30% $26.0M /celu-vs-bctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-07-31 • CIK 0001610820 ↗

In its most recent audited fiscal period (FY2025, filed 2025-07-31), BriaCell Therapeutics Corp. (BCTX) reported GAAP revenue of $76.2M (-18.4% vs. FY2024 revenue of $93.3M , and +16.9% cumulative change since FY2023) , GAAP net income of -$26.3M, operating cash flow of -$28.2M, and free cash flow of -$28.2M (-14.6% YoY). On the balance sheet, BCTX closed FY2025 with $33.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-07-31 $76.2M -$26.3M -$28.2M -$28.2M $33.6M —
FY2024 (FY) 2024-07-31 $93.3M -$4.8M -$24.1M -$24.6M $9.4M —
FY2023 (FY) 2023-07-31 $65.2M -$20.3M -$23.7M -$23.7M — —

3. BCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BriaCell Therapeutics Corp. (NASDAQ: BCTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $3.09 (+1.65% 1D, market cap $26.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, BCTX ranks #468 in composite RQD confidence.

How does BCTX compare to BYSI and ABVC in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCTX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $26.5M) and ABVC (ABVC BioPharma Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $26.7M). Among the 5-stock peer group, BCTX leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCTX?

Per BCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-07-31, CIK 0001610820), BriaCell Therapeutics Corp. generated $76.2M in revenue (-18.4% YoY), -$26.3M in net income, and -$28.2M in free cash flow against $33.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCTX last traded at $3.09 (+1.65% on volume of 60,204 shares), positioning the stock -17.38% below its 50-day simple moving average ($3.74) and -18.68% below its 200-day simple moving average ($3.80). Across its 52-week range of $2.60 to $13.09, BCTX sits at the 4.7% percentile with a 14-day RSI of 35.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.70 to $3.48).

Direct Sub-Reports: BCTX RQD Cockpit BCTX 12M Forecast BCTX Earnings & Move BCTX Dividends & DRIP BCTX Insiders & 13F BCTX Whale Options BCTX Profit Sankey BCTX News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BCTX — BriaCell Therapeutics Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-07-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

BriaCell Therapeutics Corp. (BCTX) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.09 (+1.65% 1D, market capitalization $26.5M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BriaCell Therapeutics Corp. (BCTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. It is classified as a biotechnology company. — for: its specific products, customers, or revenue model. The profile does not describe what the company sells or to whom, and the reported revenue is — across the periods provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-07-31), BriaCell Therapeutics Corp. (BCTX) reported $76.2M in annual revenue (up from $93.3M in FY2024, -18.4% YoY) and -$26.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($65.2M revenue, -$20.3M net income) through FY2025, BCTX scaled operating cash flow to -$28.2M and free cash flow to -$28.2M, backed by $33.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.60 – $13.09 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph contains no upstream or downstream links, no sector correlation data, and no proprietary signals. Second-order bottlenecks cannot be identified from the provided sources.

  • Key Question #1: Can BCTX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $76.2M and free cash flow of -$28.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BCTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BCTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BriaCell Therapeutics Corp. (BCTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BCTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BCTX Bull vs. Bear Conversation Board — What's Your Call at $3.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BCTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.95 (+29.9%)
📌 Pinned Debate

Reported cash rose from $5.0M in FY 2024 to $29.9M in FY 2025, and a SITC 2026 poster presentation is scheduled.

Here is why I am bullish on BCTX here at $3.04: Reported cash rose from $5.0M in FY 2024 to $29.9M in FY 2025, and a SITC 2026 poster presentation is scheduled.. Compare BCTX's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.89 are getting bought.

ArenaChamp_24 🐂 BULL

@BreakoutHunter Agree on the RQD 40/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.04 and keeping dry powder in case we test $2.83.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $2.52 (-17.1%)
Spot @ $3.04

The Piotroski F-Score is 1 out of 9, the whale 13F flow pillar scores 3 out of 20, and the company reports $0.0M revenue with operating

I respect the product at BriaCell Therapeutics Corp., but the stock at $3.04 is a different story. The Piotroski F-Score is 1 out of 9, the whale 13F flow pillar scores 3 out of 20, and the company reports $0.0M revenue with operating losses across all periods.. FCF yield is 0.0% and RQD sits at 40/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE